Stemness regulation in prostate cancer: prostate cancer stem cells and targeted therapy

Background Increasing evidence indicates that cancer stem cells (CSCs) and cancer stem-like cells form a special subpopulation of cells that are ubiquitous in tumors. These cells exhibit similar characteristics to those of normal stem cells in tissues; moreover, they are capable of self-renewal and...

Full description

Saved in:
Bibliographic Details
Main Authors: Hao Liang, Bin Zhou, Peixin Li, Xiaoyi Zhang, Shijie Zhang, Yaozhong Zhang, Shengwen Yao, Sifeng Qu, Jun Chen
Format: Article
Language:English
Published: Taylor & Francis Group 2025-12-01
Series:Annals of Medicine
Subjects:
Online Access:https://www.tandfonline.com/doi/10.1080/07853890.2024.2442067
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1850134982859685888
author Hao Liang
Bin Zhou
Peixin Li
Xiaoyi Zhang
Shijie Zhang
Yaozhong Zhang
Shengwen Yao
Sifeng Qu
Jun Chen
author_facet Hao Liang
Bin Zhou
Peixin Li
Xiaoyi Zhang
Shijie Zhang
Yaozhong Zhang
Shengwen Yao
Sifeng Qu
Jun Chen
author_sort Hao Liang
collection DOAJ
description Background Increasing evidence indicates that cancer stem cells (CSCs) and cancer stem-like cells form a special subpopulation of cells that are ubiquitous in tumors. These cells exhibit similar characteristics to those of normal stem cells in tissues; moreover, they are capable of self-renewal and differentiation, as well as high tumorigenicity and drug resistance. In prostate cancer (PCa), it is difficult to kill these cells using androgen signaling inhibitors and chemotherapy drugs. Consequently, the residual prostate cancer stem cells (PCSCs) mediate tumor recurrence and progression.Objective This review aims to provide a comprehensive and up-to-date overview of PCSCs, with a particular emphasis on potential therapeutic strategies targeting these cells.Methods After searching in PubMed and Embase databases using ‘prostate cancer’ and ‘cancer stem cells’ as keywords, studies related were compiled and examined.Results In this review, we detail the origin and characteristics of PCSCs, introduce the regulatory pathways closely related to CSC survival and stemness maintenance, and discuss the link between epithelial–mesenchymal transition, tumor microenvironment and tumor stemness. Furthermore, we introduce the currently available therapeutic strategies targeting CSCs, including signaling pathway inhibitors, anti-apoptotic protein inhibitors, microRNAs, nanomedicine, and immunotherapy. Lastly, we summarize the limitations of current CSC research and mention future research directions.Conclusion A deeper understanding of the regulatory network and molecular markers of PCSCs could facilitate the development of novel therapeutic strategies targeting these cells. Previous preclinical studies have demonstrated the potential of this treatment approach. In the future, this may offer alternative treatment options for PCa patients.
format Article
id doaj-art-0f7f13f8a8734b00bc67802cdec9fdd6
institution OA Journals
issn 0785-3890
1365-2060
language English
publishDate 2025-12-01
publisher Taylor & Francis Group
record_format Article
series Annals of Medicine
spelling doaj-art-0f7f13f8a8734b00bc67802cdec9fdd62025-08-20T02:31:34ZengTaylor & Francis GroupAnnals of Medicine0785-38901365-20602025-12-0157110.1080/07853890.2024.2442067Stemness regulation in prostate cancer: prostate cancer stem cells and targeted therapyHao Liang0Bin Zhou1Peixin Li2Xiaoyi Zhang3Shijie Zhang4Yaozhong Zhang5Shengwen Yao6Sifeng Qu7Jun Chen8Department of Urology, Qilu Hospital of Shandong University (Qingdao), Qingdao, ChinaDepartment of Urology, Qilu Hospital of Shandong University, Jinan, ChinaDepartment of Urology, Qilu Hospital of Shandong University, Jinan, ChinaDepartment of Urology, Qilu Hospital of Shandong University, Jinan, ChinaDepartment of Urology, Qilu Hospital of Shandong University, Jinan, ChinaDepartment of Urology, Qilu Hospital of Shandong University, Jinan, ChinaDepartment of Urology, Qilu Hospital of Shandong University, Jinan, ChinaDepartment of Urology, Qilu Hospital of Shandong University (Qingdao), Qingdao, ChinaDepartment of Urology, Qilu Hospital of Shandong University (Qingdao), Qingdao, ChinaBackground Increasing evidence indicates that cancer stem cells (CSCs) and cancer stem-like cells form a special subpopulation of cells that are ubiquitous in tumors. These cells exhibit similar characteristics to those of normal stem cells in tissues; moreover, they are capable of self-renewal and differentiation, as well as high tumorigenicity and drug resistance. In prostate cancer (PCa), it is difficult to kill these cells using androgen signaling inhibitors and chemotherapy drugs. Consequently, the residual prostate cancer stem cells (PCSCs) mediate tumor recurrence and progression.Objective This review aims to provide a comprehensive and up-to-date overview of PCSCs, with a particular emphasis on potential therapeutic strategies targeting these cells.Methods After searching in PubMed and Embase databases using ‘prostate cancer’ and ‘cancer stem cells’ as keywords, studies related were compiled and examined.Results In this review, we detail the origin and characteristics of PCSCs, introduce the regulatory pathways closely related to CSC survival and stemness maintenance, and discuss the link between epithelial–mesenchymal transition, tumor microenvironment and tumor stemness. Furthermore, we introduce the currently available therapeutic strategies targeting CSCs, including signaling pathway inhibitors, anti-apoptotic protein inhibitors, microRNAs, nanomedicine, and immunotherapy. Lastly, we summarize the limitations of current CSC research and mention future research directions.Conclusion A deeper understanding of the regulatory network and molecular markers of PCSCs could facilitate the development of novel therapeutic strategies targeting these cells. Previous preclinical studies have demonstrated the potential of this treatment approach. In the future, this may offer alternative treatment options for PCa patients.https://www.tandfonline.com/doi/10.1080/07853890.2024.2442067Prostate cancercancer stem-like cellcancer stem cellstumor heterogeneitystemnesstargeted therapy
spellingShingle Hao Liang
Bin Zhou
Peixin Li
Xiaoyi Zhang
Shijie Zhang
Yaozhong Zhang
Shengwen Yao
Sifeng Qu
Jun Chen
Stemness regulation in prostate cancer: prostate cancer stem cells and targeted therapy
Annals of Medicine
Prostate cancer
cancer stem-like cell
cancer stem cells
tumor heterogeneity
stemness
targeted therapy
title Stemness regulation in prostate cancer: prostate cancer stem cells and targeted therapy
title_full Stemness regulation in prostate cancer: prostate cancer stem cells and targeted therapy
title_fullStr Stemness regulation in prostate cancer: prostate cancer stem cells and targeted therapy
title_full_unstemmed Stemness regulation in prostate cancer: prostate cancer stem cells and targeted therapy
title_short Stemness regulation in prostate cancer: prostate cancer stem cells and targeted therapy
title_sort stemness regulation in prostate cancer prostate cancer stem cells and targeted therapy
topic Prostate cancer
cancer stem-like cell
cancer stem cells
tumor heterogeneity
stemness
targeted therapy
url https://www.tandfonline.com/doi/10.1080/07853890.2024.2442067
work_keys_str_mv AT haoliang stemnessregulationinprostatecancerprostatecancerstemcellsandtargetedtherapy
AT binzhou stemnessregulationinprostatecancerprostatecancerstemcellsandtargetedtherapy
AT peixinli stemnessregulationinprostatecancerprostatecancerstemcellsandtargetedtherapy
AT xiaoyizhang stemnessregulationinprostatecancerprostatecancerstemcellsandtargetedtherapy
AT shijiezhang stemnessregulationinprostatecancerprostatecancerstemcellsandtargetedtherapy
AT yaozhongzhang stemnessregulationinprostatecancerprostatecancerstemcellsandtargetedtherapy
AT shengwenyao stemnessregulationinprostatecancerprostatecancerstemcellsandtargetedtherapy
AT sifengqu stemnessregulationinprostatecancerprostatecancerstemcellsandtargetedtherapy
AT junchen stemnessregulationinprostatecancerprostatecancerstemcellsandtargetedtherapy